Document and Entity Information - USD ($)	3 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2017	May 05, 2017	Jun. 30, 2016
Document Information [Abstract]
Entity Registrant Name	MERIT MEDICAL SYSTEMS INC
Entity Central Index Key	0000856982
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		49,916,915
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 844,073,573

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 26,464	$ 19,171
Trade receivables — net of allowance for uncollectible accounts — 2017 — $1,437 and 2016 — $1,587	95,252	80,521
Employee receivables	161	198
Other receivables	4,902	5,445
Inventories	134,310	120,695
Prepaid expenses and other assets	7,778	6,226
Prepaid income taxes	2,604	2,525
Deferred income tax assets	0	8,219
Income tax refund receivables	680	423
Total current assets	272,151	243,423
PROPERTY AND EQUIPMENT:
Land and land improvements	19,454	19,379
Buildings	141,065	139,119
Manufacturing equipment	186,323	178,110
Furniture and fixtures	45,302	43,433
Leasehold improvements	30,633	30,413
Construction-in-progress	29,259	28,180
Total property and equipment	452,036	438,634
Less accumulated depreciation	(168,652)	(162,061)
Property and equipment — net	283,384	276,573
OTHER ASSETS:
Goodwill	219,911	211,927
Deferred income tax assets	2,047	171
Other assets	29,098	28,012
Total other assets	459,646	422,807
TOTAL	1,015,181	942,803
CURRENT LIABILITIES:
Trade payables	32,625	30,619
Accrued expenses	52,875	44,947
Current portion of long-term debt	16,998	10,000
Advances from employees	479	572
Income taxes payable	2,120	2,193
Total current liabilities	105,097	88,331
LONG-TERM DEBT	220,408	314,373
DEFERRED INCOME TAX LIABILITIES	20,482	25,981
LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS	438	438
DEFERRED COMPENSATION PAYABLE	9,399	9,211
DEFERRED CREDITS	2,510	2,550
OTHER LONG-TERM OBLIGATIONS	4,505	3,730
Total liabilities	362,839	444,614
COMMITMENTS AND CONTINGENCIES (Notes 5, 9, 10 and 13)
STOCKHOLDERS’ EQUITY:
Preferred stock — 5,000 shares authorized as of March 31, 2017 and December 31, 2016; no shares issued
Common stock, no par value; shares authorized — 100,000; issued and outstanding as of March 31, 2017 - 49,891 and December 31, 2016 - 44,645	344,497	206,186
Retained earnings	308,688	293,885
Accumulated other comprehensive loss	(843)	(1,882)
Total stockholders’ equity	652,342	498,189
TOTAL	1,015,181	942,803
Developed technology — net of accumulated amortization — 2017 — $57,373 and 2016 — $52,843
OTHER ASSETS:
Intangible Assets	156,414	135,358
Other — net of accumulated amortization — 2017 — $31,459 and 2016 — $30,048
OTHER ASSETS:
Intangible Assets	$ 52,176	$ 47,339

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Trade receivables, allowances	$ 1,437	$ 1,587
STOCKHOLDERS’ EQUITY:
Preferred stock shares authorized (in shares)	5,000,000	5,000,000
Preferred stock shares issued (in shares)	0	0
Common stock par value (in USD per share)
Common stock shares authorized (in shares)	100,000,000	100,000,000
Common stock shares issued (in shares)	49,891,000	44,645,000
Common stock shares outstanding (in shares)	49,891,000	44,645,000
Developed technology
OTHER ASSETS:
Intangibles, accumulated amortization	$ 57,373	$ 52,843
Other
OTHER ASSETS:
Intangibles, accumulated amortization	$ 31,459	$ 30,048

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
NET SALES	$ 171,069	$ 138,077
COST OF SALES	95,127	77,977
GROSS PROFIT	75,942	60,100
OPERATING EXPENSES:
Selling, general and administrative	57,771	41,704
Research and development	12,525	10,588
Contingent consideration expense	37	102
Total operating expenses	70,333	52,394
INCOME FROM OPERATIONS	5,609	7,706
OTHER INCOME (EXPENSE):
Interest income	83	9
Interest expense	(2,706)	(1,329)
Gain on bargain purchase	12,243	0
Other income (expense) — net	264	(480)
Other income (expense) — net	9,884	(1,800)
INCOME BEFORE INCOME TAXES	15,493	5,906
INCOME TAX EXPENSE	690	1,555
NET INCOME	$ 14,803	$ 4,351
EARNINGS PER COMMON SHARE:
Basic (in dollars per share)	$ 0.33	$ 0.10
Diluted (in dollars per share)	$ 0.32	$ 0.10
AVERAGE COMMON SHARES:
Basic (in shares)	44,830	44,275
Diluted (in shares)	45,820	44,579

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 14,803	$ 4,351
Other comprehensive income (loss):
Cash Flow Hedges	837	(729)
Less income tax benefit (expense)	(326)	284
Foreign currency translation adjustment	780	1,228
Less income tax benefit (expense)	(252)	(90)
Total other comprehensive income	1,039	693
Total comprehensive income	$ 15,842	$ 5,044

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 14,803,000	$ 4,351,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	12,759,000	9,705,000
Gain on bargain purchase	(12,243,000)	0
Losses on sales and/or abandonment of property and equipment	212,000	29,000
Write-off of patents and intangible assets	18,000	0
Amortization of deferred credits	(40,000)	(43,000)
Amortization of long-term debt issuance costs	171,000	257,000
Deferred income taxes	(387,000)	170,000
Excess tax benefits from stock-based compensation	0	3,000
Stock-based compensation expense	577,000	624,000
Changes in operating assets and liabilities, net of effects from acquisitions:
Trade receivables	(5,757,000)	(835,000)
Employee receivables	36,000	(43,000)
Other receivables	374,000	1,367,000
Inventories	844,000	(2,272,000)
Prepaid expenses and other assets	229,000	(498,000)
Prepaid income taxes	(89,000)	(38,000)
Income tax refund receivables	(350,000)	424,000
Other assets	(1,172,000)	109,000
Trade payables	1,039,000	2,400,000
Accrued expenses	3,285,000	(3,936,000)
Advances from employees	(86,000)	(388,000)
Income taxes payable	(22,000)	578,000
Deferred compensation payable	187,000	(305,000)
Other long-term obligations	790,000	(76,000)
Total adjustments	375,000	7,232,000
Net cash provided by operating activities	15,178,000	11,583,000
Capital expenditures for:
Property and equipment	(10,178,000)	(10,991,000)
Intangible assets	(668,000)	(482,000)
Proceeds from sale of cost method investment	0	1,089,000
Proceeds from the sale of property and equipment	3,000	0
Cash paid in acquisitions, net of cash acquired	(47,461,000)	(21,500,000)
Net cash used in investing activities	(58,304,000)	(31,884,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	138,569,000	557,000
Payment of offering costs related to issuance of common stock	(833,000)	0
Proceeds from issuance of long-term debt	83,723,000	55,184,000
Payments on long-term debt	(170,723,000)	(34,376,000)
Excess tax benefits from stock-based compensation	0	(3,000)
Contingent payments related to acquisitions	(15,000)	(167,000)
Net cash provided by financing activities	50,721,000	21,195,000
EFFECT OF EXCHANGE RATES ON CASH	(302,000)	91,000
NET INCREASE IN CASH AND CASH EQUIVALENTS	7,293,000	985,000
CASH AND CASH EQUIVALENTS:
Beginning of period	19,171,000	4,177,000
End of period	26,464,000	5,162,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest (net of capitalized interest of $119 and $91, respectively)	2,743,000	1,378,000
Income taxes	1,571,000	428,000
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases in accounts payable	756,000	1,584,000
Contingent receivable in exchange for sale of cost method investment	$ 0	$ 681,000

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	Basis of Presentation. The interim consolidated financial statements of Merit Medical Systems, Inc. ("Merit," "we" or "us") for the three-month periods ended March 31, 2017 and 2016 are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of March 31, 2017 and December 31, 2016, and our results of operations and cash flows for the three-month periods ended March 31, 2017 and 2016. The results of operations for the three-month periods ended March 31, 2017 and 2016 are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K (the "2016 Form 10-K") for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2017.

Stock Based Compensation

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Employee Stock Purchase Plan Stock Options and Warrants

Stock-Based Compensation. Stock-based compensation expense before income tax expense for the three-month periods ended March 31, 2017 and 2016, consisted of the following (in thousands):



	Three Months Ended March 31,
	2017		2016
Cost of goods sold	$	96	$	123
Research and development	52		42
Selling, general, and administrative	429		459
Stock-based compensation expense before taxes	$	577	$	624

As of March 31, 2017, the total remaining unrecognized compensation cost related to non-vested stock options, net of expected forfeitures, was approximately $7.2 million and is expected to be recognized over a weighted average period of 3.19 years.

During the three-month period ended March 31, 2017, we did not grant any new stock-based awards. During the three-month period ended March 31, 2016, we granted stock-based awards representing 563,500 shares of our common stock. We use the Black-Scholes methodology to value the stock-based compensation expense for options. In applying the Black-Scholes methodology to the options granted during the three-month period ended March 31, 2016, the fair value of our stock-based awards granted was estimated using the following assumptions for the periods indicated below:



		Three months ended
		March 31, 2016
Risk-free interest rate		1.4%
Expected option life		5.0 years
Expected dividend yield		—%
Expected price volatility		37.06%

For the purpose of the foregoing analysis, the average risk-free interest rate is determined using the U.S. Treasury rate in effect as of the date of grant, based on the expected term of the stock option. We determine the expected term of the stock options using the historical exercise behavior of employees. The expected price volatility was determined using a weighted average of daily historical volatility of our stock price over the corresponding expected option life and implied volatility based on recent trends of the daily historical volatility. For options with a vesting period, compensation expense is recognized on a straight-line basis over the service period, which corresponds to the vesting period.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Earnings Per Common Share (EPS)

3 Months Ended

Mar. 31, 2017

Earnings Per Share, Basic and Diluted [Abstract]

Earnings Per Common Share (EPS)

Earnings Per Common Share (EPS). The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):



	Net Income		Shares	Per Share Amount
Three-month period ended March 31, 2017:
Basic EPS	$	14,803	44,830	$	0.33
Effect of dilutive stock options and warrants			990

Diluted EPS	$	14,803	45,820	$	0.32

Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			96

Three-month period ended March 31, 2016:
Basic EPS	$	4,351	44,275	$	0.10
Effect of dilutive stock options and warrants			304

Diluted EPS	$	4,351	44,579	$	0.10

Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			978

Acquisitions

3 Months Ended

Mar. 31, 2017

Business Combinations [Abstract]

Acquisitions

. On January 31, 2017, we signed a purchase agreement with Argon Medical Devices, Inc. ("Argon") to acquire Argon’s critical care business including a manufacturing facility in Yishun, Singapore, the related commercial operations in Europe and Japan, and certain inventories and intellectual property rights within the United States. We made an initial payment of approximately $10.9 million which is subject to a working capital adjustment. We accounted for the acquisition as a business combination.

Acquisition-related costs associated with the Argon acquisition during the three-month period ended March 31, 2017, which are included in selling, general, and administrative expenses in the accompanying consolidated statements of income, were approximately $1.1 million. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the three-month period ended March 31, 2017, our net sales of Argon products were approximately $7.2 million. It is not practical to separately report the earnings related to the Argon acquisition, as we cannot split out sales costs related solely to the products we acquired from Argon, principally because our sales representatives sell multiple products (including the products we acquired from Argon) in our cardiovascular business segment.

The assets and liabilities in the initial purchase price allocation for the Argon acquisition are stated at fair value based on estimates of fair value using available information and making assumptions management believes are reasonable. The following table summarizes the preliminary purchase price allocated to the net tangible and intangible assets acquired and liabilities assumed (in thousands):



Assets Acquired
Cash and cash equivalents	$	1,436
Trade receivables	8,351
Inventories	12,217
Prepaid expenses	1,275
Property and equipment	2,667
Deferred tax assets	184
Intangibles
Developed technology	2,600
Customer lists	1,300
Trademarks	1,500
Total assets acquired	31,530

Liabilities Assumed
Trade payables	(2,306		)
Accrued expenses	(5,083		)
Income taxes payable	(2		)
Deferred income tax liabilities	(999		)
Total liabilities assumed	(8,390		)

Total net assets acquired	23,140
Gain on bargain purchase	(12,243		)
Total purchase price	$	10,897

With respect to the Argon assets, we are amortizing developed technology over seven years and customer lists on an accelerated basis over five years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of five years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 6.0 years.

The total fair value of the net assets acquired from Argon, including identifiable intangible assets, exceeded the purchase price resulting in a gain on bargain purchase which was recorded within other income (expense) in our consolidated statements of income for the three-month period ended March 31, 2017. We believe the reason for the provisional gain on bargain purchase was a result of the divestiture of a non-strategic, slow growth critical care business for Argon. It is our understanding that the divestiture allows Argon to focus on its higher growth interventional portfolio. Given the circumstances of this acquisition, which closed during the first quarter, as well as the complexity of the transaction, the entire purchase price allocation disclosed herein (as well as the gain on bargain purchase) is considered provisional at this time and subject to adjustment to reflect information obtained about factors and circumstances that existed as of the acquisition date that if known would have affected the measurement of the amounts recognized as of that date. We are currently reassessing whether we have correctly identified all the assets acquired and the liabilities assumed, and the measurement period remains open.

On January 31, 2017, we acquired substantially all the assets, including intellectual property covered by approximately 40 patents and pending applications, and assumed certain liabilities, of Catheter Connections, Inc. (“Catheter Connections”), in exchange for payment of $38 million, which is subject to a working capital adjustment. Catheter Connections, which is based in Salt Lake City, Utah, developed and marketed the DualCap® System, an innovative family of disinfecting products designed to protect patients from intravenous infections resulting from infusion therapy. We accounted for this acquisition as a business combination.

Acquisition-related costs associated with the Catheter Connections acquisition, which are included in selling, general and administrative expenses in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the three-month period ended March 31, 2017, our net sales of the products acquired from Catheter Connections were approximately $1.8 million. It is not practical to separately report the earnings related to the products acquired from Catheter Connections, as we cannot split out sales costs related solely to those products, principally because our sales representatives sell multiple products (including the DualCap System) in the cardiovascular business segment. The purchase price was preliminarily allocated as follows (in thousands):



Assets Acquired
Trade receivables	$	952
Inventories	2,244
Prepaid expenses and other current assets	181
Property and equipment	1,472
Intangibles
Developed technology	22,900
Customer lists	100
Trademarks	2,900
Goodwill	7,612
Total assets acquired	38,361

Liabilities Assumed
Trade payables	(338		)
Accrued expenses	(23		)
Total liabilities assumed	(361		)

Net assets acquired	$	38,000

We are amortizing the developed technology asset over 12 years, the related trademarks over 10 years, and the associated customer list over eight years. We have estimated the weighted average life of the intangible Catheter Connections assets acquired to be approximately 11.8 years.

On July 6, 2016, we acquired all the issued and outstanding shares of DFINE Inc. ("DFINE"). The DFINE acquisition added a line of vertebral augmentation products for the treatment of vertebral compression fractures ("VCF") as well as medical devices used to treat metastatic spine tumors. We made an initial payment of $97.5 million to certain DFINE stockholders on July 6, 2016 and paid approximately $578,000 related to a net working capital adjustment subject to review by Merit and the preferred stockholders of DFINE. We accounted for the acquisition as a business combination. In the three-month period ended December 31, 2016, we negotiated the final net working capital adjustment resulting in a reduction to the purchase price of approximately $1.1 million. As a result, we recorded measurement period adjustments to reduce inventories by approximately $89,000, reduce property and equipment by approximately $109,000, reduce goodwill by approximately $1.2 million, reduce accrued expenses by approximately $407,000 and increase the associated deferred tax liabilities by approximately $113,000. Under GAAP, measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments.

Acquisition-related costs associated with the DFINE acquisition during the year ended December 31, 2016, which were included in selling, general, and administrative expenses in the consolidated statements of income included in the 2016 Form 10-K, were approximately $1.6 million. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2016, our net sales of DFINE products were approximately $13.5 million. It is not practical to separately report the earnings related to the DFINE acquisition, as we cannot split out sales costs related solely to the DFINE products, principally because our sales representatives sell multiple products (including DFINE products) in the cardiovascular business segment.

The purchase price was allocated to the net tangible and intangible assets acquired and liabilities assumed, based on estimated fair values, as follows (in thousands):



Assets Acquired
Trade receivables	$	4,054
Other receivables	6
Inventories	8,585
Prepaid expenses	630
Property and equipment	1,630
Other long-term assets	145
Intangibles
Developed technology	67,600
Customer lists	2,400
Trademarks	4,400
Goodwill	24,818
Total assets acquired	114,268

Liabilities Assumed
Trade payables	(1,790		)
Accrued expenses	(5,298		)
Deferred income tax liabilities - current	(701		)
Deferred income tax liabilities - noncurrent	(10,844		)
Total liabilities assumed	(18,633		)

Net assets acquired, net of cash received of $1,327	$	95,635

The gross amount of trade receivables we acquired in the DFINE acquisition was approximately $4.3 million, of which approximately $224,000 was expected to be uncollectible or returned. With respect to the DFINE assets, we are amortizing developed technology over fifteen years and customer lists on an accelerated basis over nine years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of fifteen years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 14.8 years.

On February 4, 2016, we purchased the HeRO® Graft device and other related assets from CryoLife, Inc., a developer of medical devices based in Kennesaw, Georgia ("CryoLife"). The HeRO Graft is a fully subcutaneous vascular access system intended for use in maintaining long-term vascular access for chronic hemodialysis patients who have failing fistulas, grafts or are catheter dependent due to a central venous blockage. The purchase price was $18.5 million, which was paid in full during 2016. We accounted for this acquisition as a business combination. The purchase price was allocated as follows (in thousands):



Assets Acquired
Inventories	$	2,455
Property and equipment	290
Intangibles
Developed technology	12,100
Trademarks	700
Customers Lists	400
Goodwill	2,555

Total assets acquired	$	18,500

We are amortizing the developed HeRO Graft technology asset over ten years, the related trademarks over 5.5 years, and the associated customer lists over 12 years. We have estimated the weighted average life of the intangible HeRO Graft assets acquired to be approximately 9.82 years. Acquisition-related costs related to the HeRO Graft device and other related assets during the year ended December 31, 2016, which were included in selling, general and administrative expenses in the consolidated statements of income included in the 2016 Form 10-K, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2016, our net sales of the products acquired from CryoLife were approximately $7.1 million. It is not practical to separately report the earnings related to the products acquired from CryoLife, as we cannot split out sales costs related solely to those products, principally because our sales representatives sell multiple products (including the HeRO Graft device) in the cardiovascular business segment.

The following table summarizes our consolidated results of operations for the three-month periods ended March 31, 2017 and 2016, as well as unaudited pro forma consolidated results of operations as though the DFINE acquisition had occurred on January 1, 2015 and the acquisition of the Argon critical care business had occurred on January 1, 2016 (in thousands, except per share amounts):



	Three Months Ended				Three Months Ended
	March 31, 2017				March 31, 2016
	As Reported		Pro Forma		As Reported		Pro Forma
Net Sales	$	171,069	$	173,829	$	138,077	$	156,390
Net Income	14,803		1,725		4,351		12,281
Earnings per common share:
Basic	$	0.33	$	0.04	$	0.10	$	0.28
Diluted	$	0.32	$	0.04	$	0.10	$	0.28

The unaudited pro forma information set forth above is for informational purposes only and includes adjustments related to the step-up of acquired inventories, amortization expense of acquired intangible assets, interest expense on long-term debt and changes in the timing of the recognition of the gain on bargain purchase. The pro forma information should not be considered indicative of actual results that would have been achieved if the DFINE acquisition had occurred on January 1, 2015 and the acquisition of the Argon critical care business had occurred on January 1, 2016, or results that may be obtained in any future period. The pro forma consolidated results of operations do not include the Catheter Connections or HeRO Graft acquisitions as we do not deem the pro forma effect of these transactions to be material.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Segment Reporting

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Reporting and Foreign Operations

Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management ("CRM"), electrophysiology ("EP"), and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income.

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three-month periods ended March 31, 2017, and 2016, are as follows (in thousands):



	Three Months Ended March 31,
	2017		2016
Net Sales
Cardiovascular	$	164,787	$	132,544
Endoscopy	6,282		5,533
Total net sales	171,069		138,077

Operating income
Cardiovascular	4,004		6,648
Endoscopy	1,605		1,058
Total operating income	5,609		7,706

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Recent Accounting Pronouncements (Notes)	3 Months Ended
Recent Accounting Pronouncements (Notes)	Mar. 31, 2017
Accounting Changes and Error Corrections [Abstract]
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Financial Accounting Standards. In January 2017, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates the requirement to determine the fair value of individual assets and liabilities of a reporting unit to measure goodwill impairment. Under these amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. We adopted ASU 2017-04 effective January 1, 2017 on a prospective basis, and it did not have a material impact on our consolidated financial statements for the three months ended March 31, 2017. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which provides guidance to entities to assist with evaluating when a set of transferred assets and activities is a business and provides a screen to determine when a set is not a business. Under the new guidance, when substantially all the fair value of gross assets acquired (or disposed of) is concentrated in a single identifiable asset, or group of similar assets, the assets acquired would not represent a business. Also, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to produce outputs. We adopted ASU 2017-04 effective January 1, 2017 on a prospective basis. The implementation of ASU 2017-04 did not have a material impact on our consolidated financial statements for the three months ended March 31, 2017. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory, which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. ASU 2016-16 will be effective for us on January 1, 2018. We are currently evaluating the anticipated impact of adopting ASU 2016-16 on our consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 will be effective for us on January 1, 2018 with early adoption permitted. We do not presently anticipate that the adoption of ASU 2016-15 will have a material impact on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which requires companies to record excess tax benefits and deficiencies in income rather than the current requirement to record them through equity. ASU 2016-09 also allows companies the option to recognize forfeitures of share-based awards when they occur rather than the current requirement to make an estimate upon the grant of the awards. We adopted ASU 2016-09 effective January 1, 2017 on a prospective basis. The implementation of ASU 2016-09 did not have a material impact on our consolidated financial statements for the three months ended March 31, 2017. In February 2016, the FASB issued ASU No. 2016-02, Leases, which eliminates the current tests for lease classification under U.S. GAAP and requires lessees to recognize the right-of-use assets and related lease liabilities on the balance sheet for all leases greater than one year in duration. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of ASU 2016-02 is permitted. ASU 2016-02 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach. We are assessing the impact that ASU 2016-02 is anticipated to have on our consolidated financial statements. We currently expect that most of our operating lease commitments will be subject to the new standard and recognized as lease liabilities and right-of-use assets upon our adoption of ASU 2016-02. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, which amends the guidance regarding the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. ASU 2016-01 will be effective for us on January 1, 2018. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. Upon adoption of ASU 2016-01, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. We do not presently anticipate that the adoption of ASU 2016-01 will have a material impact on our financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, which requires all deferred tax assets and deferred tax liabilities to be presented as noncurrent within a classified balance sheet. We adopted ASU 2015-17 effective January 1, 2017 on a prospective basis and did not reclassify presentation of prior year balances. The adoption of this standard did not have a material impact on our consolidated financial statements for the three months ended March 31, 2017. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. ASU 2015-11 requires that inventory be measured at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventory measured using last-in, first-out or the retail inventory method are excluded from the scope of ASU 2015-11 which is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The implementation of ASU 2015-11 did not have a material impact on our consolidated financial statements for the three months ended March 31, 2017. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), to update the financial reporting requirements for revenue recognition. Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. This guidance is effective for us beginning on January 1, 2018, and entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. We have not yet reached a final conclusion on whether we will adopt this new standard on a prospective or retrospective basis. We are concluding the assessment phase of implementing this guidance. We have evaluated each of the five steps in Topic 606, which are as follows: 1) Identify the contract with the customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue when (or as) performance obligations are satisfied. Our preliminary conclusion is that we expect to identify similar performance obligations under ASC Topic 606 as compared with deliverables and separate units of account previously identified. As a result, we expect the timing of our revenue to remain the same in comparison to the current revenue recognition guidance. There are also certain considerations related to internal control over financial reporting that are associated with implementing Topic 606. We are currently evaluating our control framework for revenue recognition and identifying any changes that may need to be made in response to the new guidance. Disclosure requirements under the new guidance in Topic 606 have been significantly expanded in comparison to the disclosure requirements under the current guidance. Designing and implementing the appropriate controls over gathering and reporting the information required under Topic 606 is currently in process.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes. Our overall effective tax rate for the three months ended March 31, 2017 and 2016 was 4.5% and 26.3%, respectively, which resulted in a provision for income taxes of approximately $690,000 and $1.6 million, respectively. The decrease in the effective income tax rate for the first quarter of 2017, when compared to the first quarter of 2016, was due primarily to the nontaxable gain on the bargain purchase recorded in connection with the acquisition of the critical care division of Argon.

Revolving Credit Facility and Long-Term Debt

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Revolving Credit Facility and Long-Term Debt

Revolving Credit Facility and Long-term Debt. Our outstanding debt obligations as of March 31, 2017 and December 31, 2016, consisted of the following (in thousands):



	March 31, 2017			December 31, 2016
2016 Term loan	$	92,500		$	145,000
2016 Revolving credit loans	138,500			180,000
2017 Debt facility	6,998			—
Less debt issuance costs	(592		)	(627		)
Total long-term debt	237,406			324,373
Less current portion	16,998			10,000
Long-term portion	$	220,408		$	314,373

2017 Debt Facility

On February 23, 2017, we entered into a loan agreement with HSBC Bank, whereby HSBC Bank agreed to provide us with a loan in the amount of approximately $7.0 million. The loan matures on February 1, 2018, with an extension available at the Company's option, subject to certain conditions. The loan agreement bears interest at the three-month London Inter-Bank Offered Rate (“LIBOR”) plus 1.0%, which resets quarterly. The loan is secured by assets equal to the currently outstanding loan balance. The loan contains covenants, representations and warranties and other terms customary for loans of this nature. Our interest rate as of March 31, 2017 was a variable rate of 2.06%.

2016 Term Loan and Revolving Credit Loans

On July 6, 2016, we entered into a Second Amended and Restated Credit Agreement (as amended to date, the “Second Amended Credit Agreement”), with Wells Fargo Bank, National Association, as administrative agent, swingline lender and a lender, and Wells Fargo Securities, LLC, as sole lead arranger and sole bookrunner. In addition to Wells Fargo Bank, National Association, Bank of America, N.A., U.S. Bank, National Association, and HSBC Bank USA, National Association, are parties to the Second Amended Credit Agreement as lenders. The Second Amended Credit Agreement amends and restates in its entirety Merit’s previously outstanding Amended and Restated Credit Agreement and all amendments thereto. The Second Amended Credit Agreement was amended on September 28, 2016 to allow for a new revolving credit loan to our wholly-owned subsidiary and on March 20, 2017 to allow flexibility in how we apply net proceeds received from equity issuances to prepay outstanding indebtedness.

The Second Amended Credit Agreement provides for a term loan of $150 million and a revolving credit commitment up to an aggregate amount of $275 million, which includes a reserve of $25 million to make swingline loans from time to time. The term loan is payable in quarterly installments in the amounts provided in the Second Amended Credit Agreement until the maturity date of July 6, 2021, at which time the term and revolving credit loans, together with accrued interest thereon, will be due and payable. At any time prior to the maturity date, we may repay any amounts owing under all revolving credit loans, term loans, and all swingline loans in whole or in part, subject to certain minimum thresholds, without premium or penalty, other than breakage costs.

Revolving credit loans denominated in dollars and term loans made under the Second Amended Credit Agreement bear interest, at our election, at either a Base Rate or Eurocurrency Base Rate (as such terms are defined in the Second Amended Credit Agreement) plus the applicable margin, which increases as our Consolidated Total Leverage Ratio (as defined in the Second Amended Credit Agreement) increases. Revolving credit loans denominated in an Alternative Currency (as defined in the Second Amended Credit Agreement) bear interest at the Eurocurrency rate plus the applicable margin. Swingline loans bear interest at the base rate plus the applicable margin. Upon an event of default, the interest rate may be increased by 2.0%. The revolving credit commitment will also carry a commitment fee of 0.15% to 0.40% per annum on the unused portion.

The Second Amended Credit Agreement is collateralized by substantially all our assets. The Second Amended Credit Agreement contains covenants, representations and warranties and other terms customary for loans of this nature. The Second Amended Credit Agreement requires that we maintain certain financial covenants, as follows:



		Covenant Requirement
Consolidated Total Leverage Ratio (1)
	Through March 31, 2017	4.5 to 1.0
	April 1, 2017 through June 30, 2017	4.0 to 1.0
	July 1, 2017 through December 31, 2017	3.75 to 1.0
	January 1, 2018 through March 31, 2018	3.5 to 1.0
	April 1, 2018 and thereafter	3.25 to 1.0
Consolidated EBITDA (2)		1.25 to 1.0
Consolidated Net Income (3)		$0
Facility Capital Expenditures (4)		$30 million

(1)	Maximum Consolidated Total Leverage Ratio (as defined in the Second Amended Credit Agreement) as of any fiscal quarter end.
(2)	Minimum ratio of Consolidated EBITDA (as defined in the Second Amended Credit Agreement and adjusted for certain expenditures) to Consolidated Fixed Charges (as defined in the Second Amended Credit Agreement) for any period of four consecutive fiscal quarters.
(3)	Minimum level of Consolidated Net Income (as defined in the Second Amended Credit Agreement) for certain periods, and subject to certain adjustments.
(4)	Maximum level of the aggregate amount of all Facility Capital Expenditures (as defined in the Second Amended Credit Agreement) in any fiscal year.

Additionally, the Second Amended Credit Agreement contains customary events of default and affirmative and negative covenants for transactions of this type. As of March 31, 2017, we believe we were in compliance with all covenants set forth in the Second Amended Credit Agreement.

As of March 31, 2017, we had outstanding borrowings of approximately $231.0 million under the Second Amended Credit Agreement, with available borrowings of approximately $136.5 million, based on the leverage ratio required pursuant to the Second Amended Credit Agreement. Our interest rate as of March 31, 2017 was a fixed rate of 3.12% on $46.3 million and a fixed rate of 2.98% on $128.8 million as a result of interest rate swaps (see Note 10), and a variable floating rate of 2.98% on $56.0 million. Our interest rate as of December 31, 2016 was a fixed rate of 3.12% on $45.0 million and 2.98% on $130.0 million as a result of interest rate swaps and a variable floating rate of 2.77% on approximately $150.0 million.

Future Payments

Future minimum principal payments on our long-term debt as of March 31, 2017, are as follows (in thousands):



Years Ending	Future Minimum
December 31	Principal Payments
Remaining 2017	7,500
2018	19,498
2019	15,000
2020	17,500
2021	178,500
Total future minimum principal payments	$	237,998

Derivatives

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivatives

General. Our earnings and cash flows are subject to fluctuations due to changes in interest rates and foreign currency exchange rates, and we seek to mitigate a portion of these risks by entering into derivative contracts. The derivatives we use are interest rate swaps and foreign currency forward contracts. We recognize derivatives as either assets or liabilities at fair value in the accompanying consolidated balance sheets, regardless of whether or not hedge accounting is applied. We report cash flows arising from our hedging instruments consistent with the classification of cash flows from the underlying hedged items. Accordingly, cash flows associated with our derivative programs are classified as operating activities in the accompanying consolidated statements of cash flows.

We formally document, designate and assess the effectiveness of transactions that receive hedge accounting initially and on an ongoing basis. Changes in the fair value of derivatives that qualify for hedge accounting treatment are recorded, net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders’ equity in the accompanying consolidated balance sheets. For the ineffective portions of qualifying hedges, the change in fair value is recorded through earnings in the period of change. Changes in the fair value of derivatives not designated as hedging instruments are recorded in earnings throughout the term of the derivative.

Interest Rate Risk. A portion of our debt bears interest at variable interest rates and, therefore, we are subject to variability in the cash paid for interest expense. In order to mitigate a portion of this risk, we use a hedging strategy to reduce the variability of cash flows in the interest payments associated with a portion of the variable-rate debt outstanding under our Second Amended Credit Agreement that is solely due to changes in the benchmark interest rate.

Derivatives Designated as Cash Flow Hedges

On December 19, 2012, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $150 million with Wells Fargo to fix the one-month LIBOR rate at 0.98%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). The interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid, on a monthly basis. The notional amount of the interest rate swap is reduced quarterly by 50% of the minimum principal payment due under the terms of our Second Amended Credit Agreement. The interest rate swap is scheduled to expire on December 19, 2017.

On August 5, 2016, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $42.5 million with Wells Fargo to fix the one-month LIBOR rate at 1.12%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). On a monthly basis, the interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid. The notional amount of the interest rate swap increases quarterly by an amount equal to the decrease of the hedge entered into on December 19, 2012, up to the amount of $175.0 million. The interest rate swap is scheduled to expire on July 6, 2021.

At March 31, 2017 and 2016, our interest rate swaps qualified as cash flow hedges. The fair value of our interest rate swaps at March 31, 2017 was an asset of approximately $5.4 million, which was partially offset by approximately $2.1 million in deferred taxes. The fair value of our interest rate swap at December 31, 2016 was an asset of approximately $5.0 million, which was offset by approximately $1.9 million in deferred taxes.

Foreign Currency Risk. We operate on a global basis and are exposed to the risk that our financial condition, results of operations, and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. Our policy is to enter into foreign currency derivative contracts with maturities of up to two years. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and balances denominated in Euros, British Pounds, Chinese Yuan Renminbi, Mexican Pesos, Brazilian Reals, Australian Dollars, Hong Kong Dollars, Swiss Francs, Swedish Krona, Canadian Dollars, Singapore Dollars, Japanese Yen, Korean Won, and Danish Krone. Our consolidated financial statements are denominated in, and our principal currency is, the U.S. Dollar. We do not use derivative financial instruments for trading or speculative purposes. We are not subject to any credit risk contingent features related to our derivative contracts, and counterparty risk is managed by allocating derivative contracts among several major financial institutions.

Derivatives Designated as Cash Flow Hedges

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any (i.e., the ineffective portion) or hedge components excluded from the assessment of effectiveness, are recognized in earnings during the current period. We enter into forward contracts on various foreign currencies to manage the risk associated with forecasted exchange rates which impact revenues, cost of sales, and operating expenses in various international markets. The objective of the hedges is to reduce the variability of cash flows associated with the forecasted purchase or sale of the associated foreign currencies.

We enter into approximately 100 cash flow foreign currency hedges every month. As of March 31, 2017, we had entered into foreign currency forward contracts, which qualified as cash flow hedges, with the following notional amounts (in thousands and in local currencies):



Currency	Symbol	Forward Notional Amount
Euro	EUR	9,635
Swiss Franc	CHF	1,568
Danish Krone	DKK	9,895
British Pound	GBP	3,600
Mexican Peso	MXN	88,825
Swedish Krona	SEK	15,100

Derivatives Not Designated as Cash Flow Hedges

We forecast our net exposure in various receivables and payables to fluctuations in the value of various currencies, and we enter into foreign currency forward contracts to mitigate that exposure. We enter into approximately 20 foreign currency fair value hedges every month. As of March 31, 2017, we had entered into foreign currency forward contracts related to those balance sheet accounts with the following notional amounts (in thousands and in local currencies):



Currency	Symbol	Forward Notional Amount
Euro	EUR	23,215
British Pound	GBP	824
Chinese Yuan Renminbi	CNY	40,300
Mexican Peso	MXN	14,374
Brazilian Real	BRL	3,700
Australian Dollar	AUD	4,742
Hong Kong Dollar	HKD	11,000
Swiss Franc	CHF	240
Swedish Krona	SEK	3,561
Canadian Dollar	CAD	1,320
Singapore Dollar	SGD	3,900
Japanese Yen	JPY	106,000
South Korean Won	KRW	1,500,000

Balance Sheet Presentation of Derivatives. As of March 31, 2017 and December 31, 2016, all derivatives, both those designated as hedging instruments and those that were not designated as hedging instruments, were recorded gross at fair value on our consolidated balance sheets. We are not subject to any master netting agreements.

The fair value of derivative instruments on a gross basis is as follows (in thousands):



	As of March 31, 2017				As of December 31, 2016
	Balance Sheet Location	Fair Value			Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments
Assets
Interest rate swaps	Prepaid expenses and other assets (current)	$	334		N/A
Interest rate swaps	Other assets (long-term)	5,042			Other assets (long-term)	$	4,991
Foreign currency forward contracts	Prepaid expenses and other assets (current)	298			Prepaid expenses and other assets	116
Foreign currency forward contracts	Other assets (long-term)	88			Other assets (long-term)	18

(Liabilities)
Foreign currency forward contracts	Accrued Expenses (current)	$	(119	)	Accrued Expenses	$	(275	)
Foreign currency forward contracts	Other long-term obligations	(17		)	Other long-term obligations	(18		)

Derivatives not designated as hedging instruments
Assets
Foreign currency forward contracts	Prepaid expenses and other assets (current)	$	134		Prepaid expenses and other assets (current)	$	220
(Liabilities)
Foreign currency forward contracts	Accrued Expenses (current)	(340		)	Accrued Expenses (current)	(171		)

Income Statement Presentation of Derivatives

Derivatives Designated as Cash Flow Hedges

Derivative instruments designated as cash flow hedges had the following effects, before income taxes, on other comprehensive income and net earnings in our consolidated statements of earnings, consolidated statements of comprehensive income and consolidated balance sheets (in thousands):



	Amount of Gain/(Loss) recognized in OCI						Amount of Gain/(Loss) reclassified from AOCI
	Three months ended March 31,						Three months ended March 31,
	2017		2016				2017			2016
Derivative instrument						Location in statements of income
Interest rate swaps	$	385	$	(729	)	Interest Expense	$	(104	)	$	(245	)

Foreign currency forward contracts	388		—			Revenue	1			—
						Cost of goods sold	(65		)	—

The net amount recognized in earnings during the three months ended March 31, 2017 and 2016 due to ineffectiveness and amounts excluded from the assessment of hedge effectiveness were not significant.

As of March 31, 2017, approximately $156,000, or $95,000 after taxes, was expected to be reclassified from accumulated other comprehensive income to earnings in revenue and cost of sales over the succeeding twelve months. As of March 31, 2017, approximately $334,000, or $204,000 after taxes, was expected to be reclassified from accumulated other comprehensive income to earnings in interest expense over the succeeding twelve months.

Derivatives Not Designated as Hedging Instruments

The following gains/(losses) from these derivative instruments were recognized in our consolidated statements of income for the periods presented (in thousands):



		Three months ended March 31,
		2017			2016
Derivative Instrument	Location in statements of income
Foreign currency forward contracts	Other (expense)	$	(858	)	$	(343	)

See Note 11 for more information about our derivatives.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Fair Value Measurements

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements. Our financial assets and (liabilities) carried at fair value measured on a recurring basis as of March 31, 2017 and December 31, 2016, consisted of the following (in thousands):



				Fair Value Measurements Using
	Total Fair			Quoted prices in		Significant other			Significant
	Value at			active markets		observable inputs			Unobservable inputs
Description	March 31, 2017			(Level 1)		(Level 2)			(Level 3)

Interest rate contracts (1)	$	5,376		$	—	$	5,376		$	—
Foreign currency contract assets, current and long-term (2)	$	520		$	—	$	520		$	—
Foreign currency contract liabilities, current and long-term (3)	$	(476	)	$	—	$	(476	)	$	—

				Fair Value Measurements Using
	Total Fair			Quoted prices in		Significant other			Significant
	Value at			active markets		observable inputs			Unobservable inputs
Description	December 31, 2016			(Level 1)		(Level 2)			(Level 3)

Interest rate contracts (1)	$	4,991		$	—	$	4,991		$	—
Foreign currency contracts, current and long-term (2)	$	354		$	—	$	354		$	—
Foreign currency contract liabilities, current and long-term (3)	$	(464	)	$	—	$	(464	)	$	—

(1) The fair value of the interest rate contracts is determined using Level 2 fair value inputs and is recorded as prepaid expenses and other assets (current) and other assets (long-term) in the consolidated balance sheets.

(2) The fair value of the foreign currency contract assets (including those designated as hedging instruments and those not designated as hedging instruments) is determined using Level 2 fair value inputs and is recorded as prepaid expenses and other assets (current) and other assets (long-term) in the consolidated balance sheets.

(3) The fair value of the foreign currency contract liabilities (including those designated as hedging instruments and those not designated as hedging instruments) is determined using Level 2 fair value inputs and is recorded as accrued expenses (current) or other long-term obligations in the consolidated balance sheets.

Certain of our business combinations involve the potential for the payment of future contingent consideration, generally based on a percentage of future product sales or upon attaining specified future revenue milestones. See Note 5 for further information regarding these acquisitions. The contingent consideration liability is re-measured at the estimated fair value at each reporting period with the change in fair value recognized within operating expenses in the accompanying consolidated statements of income. We measure the initial liability and re-measure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. Changes in the fair value of our contingent consideration liability during the three-month periods ended March 31, 2017 and 2016, consisted of the following (in thousands):



	Three Months Ended March 31,
	2017			2016
Beginning balance	$	683		$	1,024
Fair value adjustments recorded to income during the period	37			71
Contingent payments made	(15		)	(167		)
Ending balance	$	705		$	928

The recurring Level 3 measurement of our contingent consideration liabilities and contingent receivable includes the following significant unobservable inputs at March 31, 2017 and December 31, 2016 (amounts in thousands):



Contingent consideration asset or liability	Fair value at March 31, 2017		Valuation technique	Unobservable inputs	Range
Revenue-based payments	$	705	Discounted cash flow	Discount rate	9.9% - 15%
contingent liability			Discounted cash flow	Probability of milestone payment	100%
				Projected year of payments	2017-2028

Contingent receivable	$	528	Discounted cash flow	Discount rate	10%
asset			Discounted cash flow	Probability of milestone payment	57%
				Projected year of payments	2017-2019

Contingent consideration asset or liability	Fair value at December 31, 2016		Valuation technique	Unobservable inputs	Range
Revenue-based payments	$	683	Discounted cash flow	Discount rate	9.9% - 15%
contingent liability			Discounted cash flow	Probability of milestone payment	100%
				Projected year of payments	2017-2028

Contingent receivable	$	528	Discounted cash flow	Discount rate	10%
asset			Discounted cash flow	Probability of milestone payment	57%
				Projected year of payments	2017-2019

The contingent consideration liabilities and contingent receivable are re-measured to fair value each reporting period using projected revenues, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. An increase (decrease) in either the discount rate or the time to payment, in isolation, may result in a significantly lower (higher) fair value measurement. A decrease in the probability of any milestone payment may result in lower fair value measurements.

Our determination of the fair value of the contingent consideration liabilities and contingent receivable could change in future periods based upon our ongoing evaluation of these significant unobservable inputs. We record any such change in fair value to operating expenses in our consolidated statements of income. As of March 31, 2017, approximately $609,000 was included in other long-term obligations and $96,000 was included in accrued expenses in our consolidated balance sheet. As of December 31, 2016, approximately $595,000 was included in other long-term obligations and $88,000 was included in accrued expenses in our consolidated balance sheet. The cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) has been reflected as a cash outflow from financing activities in the accompanying consolidated statements of cash flows.

During the three-month periods ended March 31, 2017 and 2016, we had losses of approximately $18,000, and $0, respectively, related to the measurement of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

The carrying amount of cash and cash equivalents, receivables, and trade payables approximate fair value because of the immediate, short-term maturity of these financial instruments. The carrying amount of long-term debt approximates fair value, as determined by borrowing rates estimated to be available to us for debt with similar terms and conditions. The fair value of assets and liabilities whose carrying value approximates fair value is determined using Level 2 inputs, with the exception of cash and cash equivalents, which are Level 1 inputs.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and Intangible Assets. The changes in the carrying amount of goodwill for the three-month period ended March 31, 2017 were as follows (in thousands):



	2017
Goodwill balance at January 1	$	211,927
Effect of foreign exchange	372
Additions as the result of acquisitions	7,612
Goodwill balance at March 31	$	219,911

As of March 31, 2017, we had recorded $8.3 million of accumulated goodwill impairment charges. All of the goodwill balance as of March 31, 2017 and December 31, 2016, is related to our cardiovascular segment.

Other intangible assets at March 31, 2017 and December 31, 2016, consisted of the following (in thousands):



	March 31, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Patents	$	14,780	$	(3,288	)	$	11,492
Distribution agreements	6,626		(3,770		)	2,856
License agreements	20,745		(3,745		)	17,000
Trademarks	16,786		(3,658		)	13,128
Covenants not to compete	1,028		(944		)	84
Customer lists	23,670		(16,054		)	7,616

Total	$	83,635	$	(31,459	)	$	52,176



	December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Patents	$	14,130	$	(3,165	)	$	10,965
Distribution agreements	6,626		(3,527		)	3,099
License agreements	20,695		(3,422		)	17,273
Trademarks	12,380		(3,330		)	9,050
Covenants not to compete	1,028		(936		)	92
Customer lists	22,261		(15,401		)	6,860
Royalty agreements	267		(267		)	—

Total	$	77,387	$	(30,048	)	$	47,339

Aggregate amortization expense for the three-month periods ended March 31, 2017 and 2016 was approximately $6.2 million and $3.9 million respectively.

Estimated amortization expense for the developed technology and other intangible assets for the next five years consists of the following as of March 31, 2017 (in thousands):



Year Ending December 31
Remaining 2017	$	18,457
2018	24,063
2019	23,702
2020	22,619
2021	16,172

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies. In the ordinary course of business, we are involved in various claims and litigation matters. These claims and litigation matters may include actions involving product liability, intellectual property, contractual, and employment matters. We do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs for these matters such as outside counsel fees and expenses are charged to expense in the period incurred. In October 2016, we received a subpoena from the U.S. Department of Justice seeking information on certain of our marketing and promotional practices. We are in the process of responding to the subpoena, which we anticipate will continue during 2017. We have incurred, and anticipate that we will continue to incur, substantial costs in connection with the matter. We incurred approximately $4.8 million and $1.0 million in expenses in the three-month periods ended March 31, 2017 and December 31, 2016, respectively, responding to the inquiry from the U.S. Department of Justice. We expect that these expenses will be in a similar range in subsequent quarters and may potentially be higher, depending on the progress of the investigation and other factors beyond our control. The investigation is ongoing and at this stage we are unable to predict its scope, duration or outcome. Investigations such as this may result in the imposition of, among other things, significant damages, injunctions, fines or civil or criminal claims or penalties against our company or individuals. In the event of unexpected further developments, it is possible that the ultimate resolution of any of the foregoing matters, or other similar matters, if resolved in a manner unfavorable to us, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs for these matters, such as outside counsel fees and expenses, are charged to expense in the period incurred.

Issuance of Common Stock	3 Months Ended
Issuance of Common Stock	Mar. 31, 2017
Equity [Abstract]
Issuance of Common Stock	Issuance of Common Stock. On March 28, 2017, we closed a public offering of 5,175,000 shares of Common Stock and received proceeds of approximately $136.5 million, which is net of approximately $8.8 million in underwriting discounts and commissions and approximately $833,000 in other direct cost incurred and paid by us in connection with this equity offering. The net proceeds from the offering were used primarily to repay outstanding indebtedness under our Second Amended Credit Agreement (including our term loan and revolving credit loans).

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	The interim consolidated financial statements of Merit Medical Systems, Inc. ("Merit," "we" or "us") for the three-month periods ended March 31, 2017 and 2016 are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of March 31, 2017 and December 31, 2016, and our results of operations and cash flows for the three-month periods ended March 31, 2017 and 2016. The results of operations for the three-month periods ended March 31, 2017 and 2016 are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K (the "2016 Form 10-K") for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (the "SEC") on March 1, 2017.
Derivatives	General. Our earnings and cash flows are subject to fluctuations due to changes in interest rates and foreign currency exchange rates, and we seek to mitigate a portion of these risks by entering into derivative contracts. The derivatives we use are interest rate swaps and foreign currency forward contracts. We recognize derivatives as either assets or liabilities at fair value in the accompanying consolidated balance sheets, regardless of whether or not hedge accounting is applied. We report cash flows arising from our hedging instruments consistent with the classification of cash flows from the underlying hedged items. Accordingly, cash flows associated with our derivative programs are classified as operating activities in the accompanying consolidated statements of cash flows. We formally document, designate and assess the effectiveness of transactions that receive hedge accounting initially and on an ongoing basis. Changes in the fair value of derivatives that qualify for hedge accounting treatment are recorded, net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders’ equity in the accompanying consolidated balance sheets. For the ineffective portions of qualifying hedges, the change in fair value is recorded through earnings in the period of change. Changes in the fair value of derivatives not designated as hedging instruments are recorded in earnings throughout the term of the derivative. Interest Rate Risk. A portion of our debt bears interest at variable interest rates and, therefore, we are subject to variability in the cash paid for interest expense. In order to mitigate a portion of this risk, we use a hedging strategy to reduce the variability of cash flows in the interest payments associated with a portion of the variable-rate debt outstanding under our Second Amended Credit Agreement that is solely due to changes in the benchmark interest rate. Derivatives Designated as Cash Flow Hedges On December 19, 2012, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $150 million with Wells Fargo to fix the one-month LIBOR rate at 0.98%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). The interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid, on a monthly basis. The notional amount of the interest rate swap is reduced quarterly by 50% of the minimum principal payment due under the terms of our Second Amended Credit Agreement. The interest rate swap is scheduled to expire on December 19, 2017. On August 5, 2016, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $42.5 million with Wells Fargo to fix the one-month LIBOR rate at 1.12%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). On a monthly basis, the interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid. The notional amount of the interest rate swap increases quarterly by an amount equal to the decrease of the hedge entered into on December 19, 2012, up to the amount of $175.0 million. The interest rate swap is scheduled to expire on July 6, 2021. At March 31, 2017 and 2016, our interest rate swaps qualified as cash flow hedges. The fair value of our interest rate swaps at March 31, 2017 was an asset of approximately $5.4 million, which was partially offset by approximately $2.1 million in deferred taxes. The fair value of our interest rate swap at December 31, 2016 was an asset of approximately $5.0 million, which was offset by approximately $1.9 million in deferred taxes. Foreign Currency Risk. We operate on a global basis and are exposed to the risk that our financial condition, results of operations, and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. Our policy is to enter into foreign currency derivative contracts with maturities of up to two years. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and balances denominated in Euros, British Pounds, Chinese Yuan Renminbi, Mexican Pesos, Brazilian Reals, Australian Dollars, Hong Kong Dollars, Swiss Francs, Swedish Krona, Canadian Dollars, Singapore Dollars, Japanese Yen, Korean Won, and Danish Krone. Our consolidated financial statements are denominated in, and our principal currency is, the U.S. Dollar. We do not use derivative financial instruments for trading or speculative purposes. We are not subject to any credit risk contingent features related to our derivative contracts, and counterparty risk is managed by allocating derivative contracts among several major financial institutions. Derivatives Designated as Cash Flow Hedges For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any (i.e., the ineffective portion) or hedge components excluded from the assessment of effectiveness, are recognized in earnings during the current period. We enter into forward contracts on various foreign currencies to manage the risk associated with forecasted exchange rates which impact revenues, cost of sales, and operating expenses in various international markets. The objective of the hedges is to reduce the variability of cash flows associated with the forecasted purchase or sale of the associated foreign currencies.

Inventories (Tables)

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventories at March 31, 2017 and December 31, 2016 consisted of the following (in thousands):



	March 31,		December 31,
	2017		2016
Finished goods	$	69,130	$	63,852
Work-in-process	15,724		11,008
Raw materials	49,456		45,835

Total	$	134,310	$	120,695

Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Stock-based compensation expense before income tax expense for the three-month periods ended March 31, 2017 and 2016, consisted of the following (in thousands):



	Three Months Ended March 31,
	2017		2016
Cost of goods sold	$	96	$	123
Research and development	52		42
Selling, general, and administrative	429		459
Stock-based compensation expense before taxes	$	577	$	624

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

In applying the Black-Scholes methodology to the options granted during the three-month period ended March 31, 2016, the fair value of our stock-based awards granted was estimated using the following assumptions for the periods indicated below:



		Three months ended
		March 31, 2016
Risk-free interest rate		1.4%
Expected option life		5.0 years
Expected dividend yield		—%
Expected price volatility		37.06%

Earnings Per Common Share (EPS) (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Share, Basic and Diluted [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):



	Net Income		Shares	Per Share Amount
Three-month period ended March 31, 2017:
Basic EPS	$	14,803	44,830	$	0.33
Effect of dilutive stock options and warrants			990

Diluted EPS	$	14,803	45,820	$	0.32

Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			96

Three-month period ended March 31, 2016:
Basic EPS	$	4,351	44,275	$	0.10
Effect of dilutive stock options and warrants			304

Diluted EPS	$	4,351	44,579	$	0.10

Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			978

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2017

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The purchase price was allocated to the net tangible and intangible assets acquired and liabilities assumed, based on estimated fair values, as follows (in thousands):



Assets Acquired
Trade receivables	$	4,054
Other receivables	6
Inventories	8,585
Prepaid expenses	630
Property and equipment	1,630
Other long-term assets	145
Intangibles
Developed technology	67,600
Customer lists	2,400
Trademarks	4,400
Goodwill	24,818
Total assets acquired	114,268

Liabilities Assumed
Trade payables	(1,790		)
Accrued expenses	(5,298		)
Deferred income tax liabilities - current	(701		)
Deferred income tax liabilities - noncurrent	(10,844		)
Total liabilities assumed	(18,633		)

Net assets acquired, net of cash received of $1,327	$	95,635

The purchase price was preliminarily allocated as follows (in thousands):



Assets Acquired
Trade receivables	$	952
Inventories	2,244
Prepaid expenses and other current assets	181
Property and equipment	1,472
Intangibles
Developed technology	22,900
Customer lists	100
Trademarks	2,900
Goodwill	7,612
Total assets acquired	38,361

Liabilities Assumed
Trade payables	(338		)
Accrued expenses	(23		)
Total liabilities assumed	(361		)

Net assets acquired	$	38,000

The purchase price was allocated as follows (in thousands):



Assets Acquired
Inventories	$	2,455
Property and equipment	290
Intangibles
Developed technology	12,100
Trademarks	700
Customers Lists	400
Goodwill	2,555

Total assets acquired	$	18,500

The following table summarizes the preliminary purchase price allocated to the net tangible and intangible assets acquired and liabilities assumed (in thousands):



Assets Acquired
Cash and cash equivalents	$	1,436
Trade receivables	8,351
Inventories	12,217
Prepaid expenses	1,275
Property and equipment	2,667
Deferred tax assets	184
Intangibles
Developed technology	2,600
Customer lists	1,300
Trademarks	1,500
Total assets acquired	31,530

Liabilities Assumed
Trade payables	(2,306		)
Accrued expenses	(5,083		)
Income taxes payable	(2		)
Deferred income tax liabilities	(999		)
Total liabilities assumed	(8,390		)

Total net assets acquired	23,140
Gain on bargain purchase	(12,243		)
Total purchase price	$	10,897

Business Acquisition, Pro Forma Information



	Three Months Ended				Three Months Ended
	March 31, 2017				March 31, 2016
	As Reported		Pro Forma		As Reported		Pro Forma
Net Sales	$	171,069	$	173,829	$	138,077	$	156,390
Net Income	14,803		1,725		4,351		12,281
Earnings per common share:
Basic	$	0.33	$	0.04	$	0.10	$	0.28
Diluted	$	0.32	$	0.04	$	0.10	$	0.28

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment



	Three Months Ended March 31,
	2017		2016
Net Sales
Cardiovascular	$	164,787	$	132,544
Endoscopy	6,282		5,533
Total net sales	171,069		138,077

Operating income
Cardiovascular	4,004		6,648
Endoscopy	1,605		1,058
Total operating income	5,609		7,706

Revolving Credit Facility and Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Our outstanding debt obligations as of March 31, 2017 and December 31, 2016, consisted of the following (in thousands):



	March 31, 2017			December 31, 2016
2016 Term loan	$	92,500		$	145,000
2016 Revolving credit loans	138,500			180,000
2017 Debt facility	6,998			—
Less debt issuance costs	(592		)	(627		)
Total long-term debt	237,406			324,373
Less current portion	16,998			10,000
Long-term portion	$	220,408		$	314,373

Schedule of Long-term Debt Covenants

The Second Amended Credit Agreement requires that we maintain certain financial covenants, as follows:



		Covenant Requirement
Consolidated Total Leverage Ratio (1)
	Through March 31, 2017	4.5 to 1.0
	April 1, 2017 through June 30, 2017	4.0 to 1.0
	July 1, 2017 through December 31, 2017	3.75 to 1.0
	January 1, 2018 through March 31, 2018	3.5 to 1.0
	April 1, 2018 and thereafter	3.25 to 1.0
Consolidated EBITDA (2)		1.25 to 1.0
Consolidated Net Income (3)		$0
Facility Capital Expenditures (4)		$30 million

(1)	Maximum Consolidated Total Leverage Ratio (as defined in the Second Amended Credit Agreement) as of any fiscal quarter end.
(2)	Minimum ratio of Consolidated EBITDA (as defined in the Second Amended Credit Agreement and adjusted for certain expenditures) to Consolidated Fixed Charges (as defined in the Second Amended Credit Agreement) for any period of four consecutive fiscal quarters.
(3)	Minimum level of Consolidated Net Income (as defined in the Second Amended Credit Agreement) for certain periods, and subject to certain adjustments.
(4)	Maximum level of the aggregate amount of all Facility Capital Expenditures (as defined in the Second Amended Credit Agreement) in any fiscal year.

Schedule of Maturities of Long-term Debt

Future minimum principal payments on our long-term debt as of March 31, 2017, are as follows (in thousands):



Years Ending	Future Minimum
December 31	Principal Payments
Remaining 2017	7,500
2018	19,498
2019	15,000
2020	17,500
2021	178,500
Total future minimum principal payments	$	237,998

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Derivatives (Tables)

3 Months Ended

Mar. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Notional Amounts of Outstanding Derivative Positions



Currency	Symbol	Forward Notional Amount
Euro	EUR	9,635
Swiss Franc	CHF	1,568
Danish Krone	DKK	9,895
British Pound	GBP	3,600
Mexican Peso	MXN	88,825
Swedish Krona	SEK	15,100



Currency	Symbol	Forward Notional Amount
Euro	EUR	23,215
British Pound	GBP	824
Chinese Yuan Renminbi	CNY	40,300
Mexican Peso	MXN	14,374
Brazilian Real	BRL	3,700
Australian Dollar	AUD	4,742
Hong Kong Dollar	HKD	11,000
Swiss Franc	CHF	240
Swedish Krona	SEK	3,561
Canadian Dollar	CAD	1,320
Singapore Dollar	SGD	3,900
Japanese Yen	JPY	106,000
South Korean Won	KRW	1,500,000

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The fair value of derivative instruments on a gross basis is as follows (in thousands):



	As of March 31, 2017				As of December 31, 2016
	Balance Sheet Location	Fair Value			Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments
Assets
Interest rate swaps	Prepaid expenses and other assets (current)	$	334		N/A
Interest rate swaps	Other assets (long-term)	5,042			Other assets (long-term)	$	4,991
Foreign currency forward contracts	Prepaid expenses and other assets (current)	298			Prepaid expenses and other assets	116
Foreign currency forward contracts	Other assets (long-term)	88			Other assets (long-term)	18

(Liabilities)
Foreign currency forward contracts	Accrued Expenses (current)	$	(119	)	Accrued Expenses	$	(275	)
Foreign currency forward contracts	Other long-term obligations	(17		)	Other long-term obligations	(18		)

Derivatives not designated as hedging instruments
Assets
Foreign currency forward contracts	Prepaid expenses and other assets (current)	$	134		Prepaid expenses and other assets (current)	$	220
(Liabilities)
Foreign currency forward contracts	Accrued Expenses (current)	(340		)	Accrued Expenses (current)	(171		)

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)



	Amount of Gain/(Loss) recognized in OCI						Amount of Gain/(Loss) reclassified from AOCI
	Three months ended March 31,						Three months ended March 31,
	2017		2016				2017			2016
Derivative instrument						Location in statements of income
Interest rate swaps	$	385	$	(729	)	Interest Expense	$	(104	)	$	(245	)

Foreign currency forward contracts	388		—			Revenue	1			—
						Cost of goods sold	(65		)	—

Derivative Instruments, Gain (Loss)

The following gains/(losses) from these derivative instruments were recognized in our consolidated statements of income for the periods presented (in thousands):



		Three months ended March 31,
		2017			2016
Derivative Instrument	Location in statements of income
Foreign currency forward contracts	Other (expense)	$	(858	)	$	(343	)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Our financial assets and (liabilities) carried at fair value measured on a recurring basis as of March 31, 2017 and December 31, 2016, consisted of the following (in thousands):



				Fair Value Measurements Using
	Total Fair			Quoted prices in		Significant other			Significant
	Value at			active markets		observable inputs			Unobservable inputs
Description	March 31, 2017			(Level 1)		(Level 2)			(Level 3)

Interest rate contracts (1)	$	5,376		$	—	$	5,376		$	—
Foreign currency contract assets, current and long-term (2)	$	520		$	—	$	520		$	—
Foreign currency contract liabilities, current and long-term (3)	$	(476	)	$	—	$	(476	)	$	—

				Fair Value Measurements Using
	Total Fair			Quoted prices in		Significant other			Significant
	Value at			active markets		observable inputs			Unobservable inputs
Description	December 31, 2016			(Level 1)		(Level 2)			(Level 3)

Interest rate contracts (1)	$	4,991		$	—	$	4,991		$	—
Foreign currency contracts, current and long-term (2)	$	354		$	—	$	354		$	—
Foreign currency contract liabilities, current and long-term (3)	$	(464	)	$	—	$	(464	)	$	—

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

Changes in the fair value of our contingent consideration liability during the three-month periods ended March 31, 2017 and 2016, consisted of the following (in thousands):



	Three Months Ended March 31,
	2017			2016
Beginning balance	$	683		$	1,024
Fair value adjustments recorded to income during the period	37			71
Contingent payments made	(15		)	(167		)
Ending balance	$	705		$	928

Fair Value Inputs, Liabilities, Quantitative Information



Contingent consideration asset or liability	Fair value at March 31, 2017		Valuation technique	Unobservable inputs	Range
Revenue-based payments	$	705	Discounted cash flow	Discount rate	9.9% - 15%
contingent liability			Discounted cash flow	Probability of milestone payment	100%
				Projected year of payments	2017-2028

Contingent receivable	$	528	Discounted cash flow	Discount rate	10%
asset			Discounted cash flow	Probability of milestone payment	57%
				Projected year of payments	2017-2019

Contingent consideration asset or liability	Fair value at December 31, 2016		Valuation technique	Unobservable inputs	Range
Revenue-based payments	$	683	Discounted cash flow	Discount rate	9.9% - 15%
contingent liability			Discounted cash flow	Probability of milestone payment	100%
				Projected year of payments	2017-2028

Contingent receivable	$	528	Discounted cash flow	Discount rate	10%
asset			Discounted cash flow	Probability of milestone payment	57%
				Projected year of payments	2017-2019

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in carrying amount of goodwill

The changes in the carrying amount of goodwill for the three-month period ended March 31, 2017 were as follows (in thousands):



	2017
Goodwill balance at January 1	$	211,927
Effect of foreign exchange	372
Additions as the result of acquisitions	7,612
Goodwill balance at March 31	$	219,911

Other intangible assets

Other intangible assets at March 31, 2017 and December 31, 2016, consisted of the following (in thousands):



	March 31, 2017
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Patents	$	14,780	$	(3,288	)	$	11,492
Distribution agreements	6,626		(3,770		)	2,856
License agreements	20,745		(3,745		)	17,000
Trademarks	16,786		(3,658		)	13,128
Covenants not to compete	1,028		(944		)	84
Customer lists	23,670		(16,054		)	7,616

Total	$	83,635	$	(31,459	)	$	52,176



	December 31, 2016
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Patents	$	14,130	$	(3,165	)	$	10,965
Distribution agreements	6,626		(3,527		)	3,099
License agreements	20,695		(3,422		)	17,273
Trademarks	12,380		(3,330		)	9,050
Covenants not to compete	1,028		(936		)	92
Customer lists	22,261		(15,401		)	6,860
Royalty agreements	267		(267		)	—

Total	$	77,387	$	(30,048	)	$	47,339

Estimated amortization expense

Estimated amortization expense for the developed technology and other intangible assets for the next five years consists of the following as of March 31, 2017 (in thousands):



Year Ending December 31
Remaining 2017	$	18,457
2018	24,063
2019	23,702
2020	22,619
2021	16,172

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 69,130	$ 63,852
Work-in-process	15,724	11,008
Raw materials	49,456	45,835
Total	$ 134,310	$ 120,695

Stock Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation cost not yet recognized	$ 7.2
Compensation cost not yet recognized, period of recognition	3 years 2 months 9 days
Options granted in period (in shares)		563,500

Stock Based Compensation - Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation	$ 577	$ 624
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation	96	123
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation	52	42
Selling, general, and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation	$ 429	$ 459

Stock Based Compensation - Fair Value Calculation Assumptions (Details)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	1.40%
Expected option life	5 years
Expected dividend yield	0.00%
Expected price volatility	37.06%

Earnings Per Common Share (EPS) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share, Basic and Diluted [Abstract]
Net income, basic	$ 14,803	$ 4,351
Basic (in shares)	44,830	44,275
Basic (in dollars per share)	$ 0.33	$ 0.10
Effect of dilutive stock options and warrants (in shares)	990	304
Net income, diluted	$ 14,803	$ 4,351
Diluted (in shares)	45,820	44,579
Diluted (in dollars per share)	$ 0.32	$ 0.10
Antidilutive securities excluded from EPS (in shares)	96	978

Acquisitions - Narrative (Details) - USD ($)				3 Months Ended			12 Months Ended
Acquisitions - Narrative (Details) - USD ($)	Jan. 31, 2017	Jul. 06, 2016	Feb. 04, 2016	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Payments to acquire intangible assets				$ 668,000		$ 482,000
Goodwill acquired				7,612,000
Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Total purchase price	$ 10,897,000
Net sales related to acquisition				7,200,000
Weighted average useful life	5 years 11 months 15 days
Catheter Connections, Inc.
Business Acquisition [Line Items]
Total purchase price	$ 38,000,000
Net sales related to acquisition				1,800,000
Weighted average useful life	11 years 10 months
DFINE, Inc.
Business Acquisition [Line Items]
Total purchase price		$ 97,500,000
Net sales related to acquisition							$ 13,500,000
Trade receivables acquired, gross		4,300,000
Trade receivables, expected to be uncollectible		$ (224,000)
Weighted average useful life		14 years 10 months
Consideration paid related to net working capital adjustment		$ 578,000
Reduction of purchase price					$ 1,100,000
Measurement period adjustment, reduction in inventories					89,000
Measurement period adjustment, reduction in property and equipment					109,000
Measurement period adjustment, reduction in goodwill					1,200,000
Measurement period adjustment, reduction in accrued expenses					407,000
Measurement period adjustment, increase in deferred tax liabilities					(113,000)
HeRO®Graft
Business Acquisition [Line Items]
Total purchase price			$ 18,500,000
Weighted average useful life			9 years 9 months 25 days
Income since acquisition date				7,100,000
Developed technology
Business Acquisition [Line Items]
Intangible Assets				156,414,000	$ 135,358,000		135,358,000
Developed technology \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Useful life	7 years
Developed technology \| Catheter Connections, Inc.
Business Acquisition [Line Items]
Useful life	12 years
Developed technology \| DFINE, Inc.
Business Acquisition [Line Items]
Useful life		15 years
Developed technology \| HeRO®Graft
Business Acquisition [Line Items]
Useful life			10 years
Customer Lists
Business Acquisition [Line Items]
Intangible Assets				7,616,000		6,860,000
Customer Lists \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Useful life	5 years
Customer Lists \| Catheter Connections, Inc.
Business Acquisition [Line Items]
Useful life	8 years
Customer Lists \| DFINE, Inc.
Business Acquisition [Line Items]
Useful life		9 years
Customer Lists \| HeRO®Graft
Business Acquisition [Line Items]
Useful life			12 years
Trademarks
Business Acquisition [Line Items]
Intangible Assets				13,128,000		$ 9,050,000
Trademarks \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Useful life	5 years
Trademarks \| Catheter Connections, Inc.
Business Acquisition [Line Items]
Useful life	10 years
Trademarks \| DFINE, Inc.
Business Acquisition [Line Items]
Useful life		15 years
Trademarks \| HeRO®Graft
Business Acquisition [Line Items]
Useful life			5 years 6 months
Cardiovascular Segment \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Acquisition-related costs				$ 1,100,000
Cardiovascular Segment \| DFINE, Inc.
Business Acquisition [Line Items]
Acquisition-related costs							$ 1,600,000

Acquisitions - Purchase Price Allocation (Argon Medical Devices, Inc.) (Details) - USD ($) $ in Thousands		3 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016
Business Acquisition [Line Items]
Gain on bargain purchase		$ (12,243)	$ 0
Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents		1,436
Trade receivables		8,351
Inventories		12,217
Prepaid expenses		1,275
Property and equipment		2,667
Deferred tax assets		184
Total assets acquired		31,530
Trade payables		(2,306)
Accrued expenses		(5,083)
Income taxes payable		(2)
Deferred income tax liabilities - noncurrent		(999)
Total liabilities assumed		8,390
Total net assets acquired		23,140
Gain on bargain purchase		(12,243)
Total purchase price	$ 10,897
Developed technology \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Intangibles		2,600
Customer Lists \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Intangibles		1,300
Trademarks \| Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Intangibles		$ 1,500

Acquisitions - Purchase Price Allocation (Catheter Connections, Inc.) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 219,911	$ 211,927
Catheter Connections, Inc.
Business Acquisition [Line Items]
Trade receivables	952
Inventories	2,244
Prepaid expenses	181
Property and equipment	1,472
Goodwill	7,612
Total assets acquired	38,361
Trade payables	(338)
Accrued expenses	(23)
Total liabilities assumed	361
Net assets acquired, net of cash received of $1,327	38,000
Developed technology \| Catheter Connections, Inc.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	22,900
Customer Lists \| Catheter Connections, Inc.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	100
Trademarks \| Catheter Connections, Inc.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 2,900

Acquisitions - Purchase Price Allocation (DFINE Inc. and HeRO Graft) (Details) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Feb. 04, 2016
Assets Acquired
Goodwill	$ 211,927	$ 219,911
HeRO®Graft
Assets Acquired
Inventories			$ 2,455
Property and equipment			290
Goodwill			2,555
Total assets acquired			18,500
DFINE, Inc.
Assets Acquired
Trade receivables	4,054
Other receivables	6
Inventories	8,585
Prepaid expenses	630
Property and equipment	1,630
Other long-term assets	145
Goodwill	24,818
Total assets acquired	114,268
Liabilities Assumed
Trade payables	(1,790)
Accrued expenses	(5,298)
Deferred income tax liabilities - current	(701)
Deferred income tax liabilities - noncurrent	(10,844)
Total liabilities assumed	(18,633)
Net assets acquired, net of cash received of $1,327	95,635
Cash received	1,327
Developed technology \| HeRO®Graft
Assets Acquired
Intangibles			12,100
Developed technology \| DFINE, Inc.
Assets Acquired
Intangibles	67,600
Customer lists \| HeRO®Graft
Assets Acquired
Intangibles			400
Customer lists \| DFINE, Inc.
Assets Acquired
Intangibles	2,400
Trademarks \| HeRO®Graft
Assets Acquired
Intangibles			$ 700
Trademarks \| DFINE, Inc.
Assets Acquired
Intangibles	$ 4,400

Acquisitions - Summary of Unaudited Consolidated Results of Operations, Including Proforma Results (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
As Reported
Net Sales	$ 171,069	$ 138,077
Net income	$ 14,803	$ 4,351
Basic (in dollars per share)	$ 0.33	$ 0.10
Diluted (in dollars per share)	$ 0.32	$ 0.10
Pro Forma
Net Sales, Pro Forma	$ 173,829	$ 156,390
Net Income, Pro Forma	$ 1,725	$ 12,281
Basic, Pro Forma (in dollars per share)	$ 0.04	$ 0.28
Diluted, Pro Forma (in dollars per share)	$ 0.04	$ 0.28

Segment Reporting - Operating Income (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) segment	Mar. 31, 2016 USD ($)
Segment Reporting [Abstract]
Number of Operating Segments \| segment	2
Segment Reporting Information [Line Items]
Net Sales	$ 171,069	$ 138,077
Operating income	5,609	7,706
Cardiovascular Segment
Segment Reporting Information [Line Items]
Net Sales	164,787	132,544
Operating income	4,004	6,648
Endoscopy Segment
Segment Reporting Information [Line Items]
Net Sales	6,282	5,533
Operating income	$ 1,605	$ 1,058

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Overall effective tax rate	4.50%	26.30%
Income tax expense	$ 690	$ 1,555

Revolving Credit Facility and Long-Term Debt - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Feb. 23, 2017	Dec. 31, 2016	Jul. 06, 2016
Line of Credit Facility [Line Items]
2017 Debt facility	$ 6,998	$ 7,000	$ 0
Variable rate on 2017 debt facility	2.064%
Outstanding borrowings			(237,998)
Credit Agreement
Line of Credit Facility [Line Items]
Outstanding borrowings	$ (231,000)
Maximum facility capital expenditures in the next 12 months	30,000
Remaining borrowing capacity on line of credit	136,500
Debt subject to fixed interest rate	$ 128,800		$ 130,000
Variable Rate 1 \| Credit Agreement
Line of Credit Facility [Line Items]
Variable interest rate percent	2.98222%
Debt subject to variable interest rate	$ 56,000
Variable Rate 2 \| Credit Agreement
Line of Credit Facility [Line Items]
Variable interest rate percent			2.77%
Debt subject to variable interest rate			$ 150,000
Revolving Credit Facility \| Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 275,000
Interest rate increase if in event of default	2.00%
Term Loan \| Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument, face amount				150,000
Bridge Loan \| Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity				$ 25,000
Interest Rate Swap 1 \| Credit Agreement
Line of Credit Facility [Line Items]
Fixed interest rate percent	3.115%		3.115%
Debt subject to fixed interest rate	$ 46,300		$ 45,000
Interest Rate Swap 2 \| Credit Agreement
Line of Credit Facility [Line Items]
Fixed interest rate percent	2.9825%		2.9825%
Minimum \| Revolving Credit Facility \| Credit Agreement
Line of Credit Facility [Line Items]
Commitment fee percentage	0.15%
Maximum \| Revolving Credit Facility \| Credit Agreement
Line of Credit Facility [Line Items]
Commitment fee percentage	0.40%

Revolving Credit Facility and Long-Term Debt - Principal Balances under Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Feb. 23, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Total long-term debt	$ 237,406		$ 324,373
2017 Debt facility	6,998	$ 7,000	0
Less debt issuance costs	(592)		(627)
Less current portion	16,998		10,000
Long-term portion	220,408		314,373
Term Loan
Line of Credit Facility [Line Items]
Total long-term debt	92,500		145,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Total long-term debt	$ 138,500		$ 180,000

Revolving Credit Facility and Long-Term Debt - Financial Covenants (Details) - Credit Agreement	3 Months Ended
	Mar. 31, 2017 USD ($)
Debt Instrument [Line Items]
Consolidated EBITDA	$ 0
Consolidated Net Income	0
Facility Capital Expenditures	$ 30,000,000
Through March 31, 2017 [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio	4.5
April 1, 2017 through June 30, 2017 [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio	4
July 1, 2017 through December 31, 2017 [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio	3.75
January 1, 2018 through March 31, 2018 [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio	3.5
April 1, 2018 and thereafter [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio	3.25

Revolving Credit Facility and Long-Term Debt - Future Minimum Payments on Long-term Debt (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
Remaining 2017	$ 7,500
2018	19,498
2019	15,000
2020	17,500
2021	178,500
Total long-term debt	$ 237,998

Derivatives - Narrative (Details) - USD ($)		3 Months Ended
Derivatives - Narrative (Details) - USD ($)	Dec. 19, 2012	Mar. 31, 2017	Dec. 31, 2016	Aug. 05, 2016
Derivative [Line Items]
Accumulated other comprehensive income (loss), interest rate swap, tax benefit			$ (1,941,000)
Revenue and cost of sales
Derivative [Line Items]
Amount expected to be reclassified from accumulated other comprehensive income to earnings in next twelve months, gross		$ 156,000
Amount expected to be reclassified from accumulated other comprehensive income to earnings in next twelve months, net of tax		95,000
Interest expense
Derivative [Line Items]
Amount expected to be reclassified from accumulated other comprehensive income to earnings in next twelve months, gross		334,000
Amount expected to be reclassified from accumulated other comprehensive income to earnings in next twelve months, net of tax		204,000
Interest rate swap
Derivative [Line Items]
Notional amount of derivative	$ 150,000,000			$ 42,500,000
Fixed rate	0.9825%			1.12%
Quarterly reduction of notional amount	50.00%
Accumulated other comprehensive income (loss), interest rate swap, tax benefit		$ (2,091,000)
Interest rate swap \| Maximum
Derivative [Line Items]
Notional amount of derivative				$ 175,000,000

Derivatives - Forward Notional Contracts (Details) - Mar. 31, 2017 - Foreign currency forward contracts € in Thousands, ₩ in Thousands, ¥ in Thousands, ¥ in Thousands, £ in Thousands, SGD in Thousands, SFr in Thousands, SEK in Thousands, MXN in Thousands, HKD in Thousands, DKK in Thousands, CAD in Thousands, BRL in Thousands, AUD in Thousands	CNY (¥)	DKK	MXN	CHF (SFr)	KRW (₩)	GBP (£)	CAD	JPY (¥)	SGD	SEK	EUR (€)	HKD	BRL	AUD
Not designated as hedging instrument
Derivative [Line Items]
Notional amount of derivative	¥ 40,300		MXN 14,374	SFr 240	₩ 1,500,000	£ 824	CAD 1,320	¥ 106,000	SGD 3,900	SEK 3,561	€ 23,215	HKD 11,000	BRL 3,700	AUD 4,742
Derivatives designated as cash flow hedges \| Designated as hedging instrument
Derivative [Line Items]
Notional amount of derivative		DKK 9,895	MXN 88,825	SFr 1,568		£ 3,600				SEK 15,100	€ 9,635

Derivatives - Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Designated as hedging instrument \| Interest rate swap
Derivatives, Fair Value [Line Items]
Total Asset Derivatives	$ 5,376
Designated as hedging instrument \| Interest rate swap \| Other Assets (current)
Derivatives, Fair Value [Line Items]
Total Asset Derivatives	334
Designated as hedging instrument \| Interest rate swap \| Other Assets (long-term)
Derivatives, Fair Value [Line Items]
Total Asset Derivatives	5,042	$ 4,991
Designated as hedging instrument \| Foreign currency forward contracts \| Other Assets (long-term)
Derivatives, Fair Value [Line Items]
Total Asset Derivatives	88	18
Designated as hedging instrument \| Foreign currency forward contracts \| Prepaid expenses and other assets
Derivatives, Fair Value [Line Items]
Total Asset Derivatives	298	116
Designated as hedging instrument \| Foreign currency forward contracts \| Accrued Expenses (current)
Derivatives, Fair Value [Line Items]
Total Liability Derivatives	(119)	(275)
Designated as hedging instrument \| Foreign currency forward contracts \| Other Long-term Obligations
Derivatives, Fair Value [Line Items]
Total Liability Derivatives	(17)	(18)
Not designated as hedging instrument \| Foreign currency forward contracts \| Prepaid expenses and other assets
Derivatives, Fair Value [Line Items]
Total Asset Derivatives	134	220
Not designated as hedging instrument \| Foreign currency forward contracts \| Accrued Expenses (current)
Derivatives, Fair Value [Line Items]
Total Liability Derivatives	$ (340)	$ (171)

Derivatives - Amount of Gain (Loss) Recognized in OCI and Income Statement (Details) - Derivatives designated as cash flow hedges - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Interest rate swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) recognized in OCI	$ 385	$ (729)
Interest rate swap \| Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) reclassified from AOCI	(104)	(245)
Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) recognized in OCI		0
Foreign currency forward contracts \| Revenue
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) recognized in OCI	388
Amount of Gain/(Loss) reclassified from AOCI	1	0
Foreign currency forward contracts \| Cost of goods sold
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) reclassified from AOCI	$ (65)	$ 0

Derivatives - Gain (Loss) in the Consolidated Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Not designated as hedging instrument \| Foreign currency forward contracts \| Other expense
Derivative [Line Items]
Gain (loss) on derivative	$ (858)	$ (343)

Fair Value Measurements - Financial Assets and (Liabilities) Carried at Fair Value (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate contracts	$ 0	$ 0
Foreign currency contract liabilities, current and long-term	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value		0
Foreign currency contract liabilities, current and long-term	0	0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate contracts	5,376	4,991
Foreign currency contract liabilities, current and long-term	(520)	(354)
Foreign currency contract liabilities, current and long-term	(476)	(464)
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate contracts	0	0
Foreign currency contract liabilities, current and long-term	0
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value		0
Foreign currency contract liabilities, current and long-term	0	0
Estimate of Fair Value, Fair Value Disclosure
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate contracts	5,376	4,991
Foreign currency contract liabilities, current and long-term	(520)	(354)
Foreign currency contract liabilities, current and long-term	$ (476)	$ (464)

Fair Value Measurements - Liability Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 683	$ 1,024
Fair value adjustments recorded to income during the period	37	71
Contingent payments made	(15)	(167)
Ending balance	$ 705	$ 928

Fair Value Measurements - Fair Value Inputs, Liabilities, Quantitative Information (Details) - Contingent Consideration - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration liability	$ 705,000	$ 683,000	$ 928,000	$ 1,024,000
Revenue-based Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration liability	$ 705,000	$ 683,000
Revenue-based Payments \| Discounted Cash Flow \| Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of milestone payment	100.00%	100.00%
Revenue-based Payments \| Minimum \| Discounted Cash Flow \| Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate	9.90%	9.90%
Revenue-based Payments \| Maximum \| Discounted Cash Flow \| Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate	15.00%	15.00%
Other Payments
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration asset	$ 528,000	$ 528,000
Other Payments \| Discounted Cash Flow \| Fair Value, Inputs, Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of milestone payment	57.00%	57.00%
Discount rate	10.00%	10.00%

Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of other assets	$ 18	$ 0
Other Long-term Obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	609	595
Accrued Expenses (current)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 96	$ 88

Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Goodwill [Roll Forward]
Goodwill balance at January 1	$ 211,927
Effect of foreign exchange	372
Additions as the result of acquisitions	7,612
Goodwill balance at March 31	$ 219,911

Goodwill and Intangible Assets - Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 83,635		$ 77,387
Accumulated Amortization	(31,459)	$ (30,048)	(30,048)
Net Carrying Amount	52,176	$ 47,339	47,339
Patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	14,780		14,130
Accumulated Amortization	(3,288)		(3,165)
Net Carrying Amount	11,492		10,965
Distribution agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,626		6,626
Accumulated Amortization	(3,770)		(3,527)
Net Carrying Amount	2,856		3,099
License agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	20,745		20,695
Accumulated Amortization	(3,745)		(3,422)
Net Carrying Amount	17,000		17,273
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	16,786		12,380
Accumulated Amortization	(3,658)		(3,330)
Net Carrying Amount	13,128		9,050
Covenants not to compete
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,028		1,028
Accumulated Amortization	(944)		(936)
Net Carrying Amount	84		92
Customer lists
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	23,670		22,261
Accumulated Amortization	(16,054)		(15,401)
Net Carrying Amount	$ 7,616		6,860
Royalty agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount			267
Accumulated Amortization			(267)
Net Carrying Amount			$ 0

Goodwill and Intangible Assets - Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2017	$ 18,457
2018	24,063
2019	23,702
2020	22,619
2021	$ 16,172

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Aggregate amortization expense	$ 6.2	$ 3.9
Cardiovascular Segment
Finite-Lived Intangible Assets [Line Items]
Accumulated impairment loss	$ 8.3

Issuance of Common Stock (Details) - USD ($)		3 Months Ended
Issuance of Common Stock (Details) - USD ($)	Mar. 28, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Equity [Abstract]
Common stock shares issued (in shares)	5,175,000	49,891,000		44,645,000
Proceeds from issuance of common stock	$ 136,500,000	$ 138,569,000	$ 557,000
Underwriting discounts and commissions	8,800,000
Other direct costs incurred	$ 833,000	$ 833,000	$ 0

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net capitalized interest	$ 119	$ 91
Common Stock
Company's common stock surrendered in exchange for the exercise of stock options (in shares)